According to the latest market report published by Credence Research, Inc. “Multiple Sclerosis Drugs Market – Growth, Future Prospects and Competitive Analysis, 2017 – 2025” the global multiple sclerosis drugs market was valued at US$ 16.13 Bn in 2016, and is expected to reach US$ 27.38 Bn by 2025, expanding at a CAGR of 6.3% from 2017 to 2025.
Browse the full report Multiple Sclerosis Drugs Market – Growth, Future Prospects and Competitive Analysis, 2017 – 2025 at http://www.credenceresearch.com/report/multiple-sclerosis-drugs-market
Market Insights
Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease of the central nervous system. MS is the most common neurological disease in adult and women; It is estimated that 2.3 million people in the world are affected with multiple sclerosis. For the purpose of study, global MS drugs market is segmented on the basis of molecule type such as biologics and small molecule. In the base year of 2016, biologics held largest market share growth driven by Avonex, Betaseron, CinnoVex, Extavia, Rebif, and Tysabri. However, it is also anticipated that small molecules will be released as a result of the ALKS-8700, OS-440, RPC-1063, ACT-128800 and BAF312.
MS drugs market is segmented on the basis of route of administration search as oral and parenteral route therapeutics. Currently, parenteral MS drugs held the largest market share. The growth of this segment is mainly driven by sales of Avonex, Betaseron, Copaxone, Extavia, Glatopa, Plegridy, Rebif, Zinbryta. Geographically, North America held largest MS Drugs Market share and it is estimated that it wants to show fastest growth during forecast period. Rising incidence of MS, and higher cost of treatment are prime factors that facilitate the growth of MS drugs market in North America. According to the Multiple Sclerosis Foundation, more than 400,000 people in the United States have MS, and about 200 new cases are diagnosed each week in the United States.
Market Competition Assessment:
The global multiple sclerosis drugs market is considered to be highly competitive and comprises a large number of players. However, the market is currently dominated by few players such as Bayer HealthCare, Biogen, Novartis, Teva, Genzyme (Sanofi), Acorda Therapeutics, Pfizer, GlaxoSmithKline, Acorda Therapeutics, Inc., Merck Serono, Abbvie Inc. and others.
Key Market Movements:
– Factors such as the prevalence of multiple sclerosis in some countries and higher treatment compliance are driving the growth of MS drugs market.
– Due to the high unmet needs, in the market are focusing on the development of ideal treatment, and promising pipeline molecule. Further increase in the incidence of MS would fuel the growth of MS drugs market during the forecast period.
– Adverse etiology of the disease, MSD would be a negative impact on the growth of MS drugs market.
Download Free Sample: http://www.credenceresearch.com/sample-request/58626
About:
Credence Research is a worldwide research and counseling service that serves driving organizations, governments, non-legislative associations, and not-for-benefits. Their assistance with their enduring enhancements to their execution and understanding of their most imperative objectives. Over almost a century, we’ve made a firm extraordinarily prepared for this task.
Latest Reports:
Power Plant Boilers Market: http://www.credenceresearch.com/press/global-power-plant-boilers-market
Tire Pressure Gauge Market: http://www.credenceresearch.com/report/tire-pressure-gau-market
Media Contact
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST # 429, SAN JOSE, CA 95103 US
Ph: 1-800-361-8290
E-mail: sales@credenceresearch.com